Drug Deal Disclosure Act
To require the Department of Health and Human Services to release documents, communications, and other information relating to most favored nation pricing agreements and other private or confidential drug pricing deals struck with manufacturers, and for other purposes.
This bill, HB9699, aims to make the Department of Health and Human Services release documents and information about agreements with drug companies that promise the lowest prices, known as most favored nation (MFN) agreements. These agreements can affect how much people pay for their medications. The bill requires transparency in these deals to ensure fair pricing.
The bill would impact the public by potentially lowering drug prices, making them more affordable for everyone. It would also affect drug companies and the Department of Health and Human Services, as they would need to disclose previously private agreements.
As of the last status date, the bill was introduced on July 15, 2026, and has been referred to the Committee on Energy and Commerce, along with the Committees on Ways and Means and the Budget for further review. This means it is in the early stages of the legislative process.
